A Dose Evaluation Study for the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension or Open-Angle Glaucoma

Sponsor
Mati Therapeutics Inc. (Industry)
Overall Status
Completed
CT.gov ID
NCT01481051
Collaborator
(none)
57
6
10
9.5
0.9

Study Details

Study Description

Brief Summary

The purpose of this study is to evaluate the efficacy, safety and duration of the L-PPDS (latanoprost punctal plug delivery system) at different dose levels.

Condition or Disease Intervention/Treatment Phase
Phase 2

Study Design

Study Type:
Interventional
Actual Enrollment :
57 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
PPL GLAU 12: A Phase 2 Dose Evaluation Study for the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension (OH) or Open-Angle Glaucoma (OAG)
Study Start Date :
Nov 1, 2011
Actual Primary Completion Date :
Sep 1, 2012
Actual Study Completion Date :
Sep 1, 2012

Outcome Measures

Primary Outcome Measures

  1. IOP change from baseline [12 weeks to baseline]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Male or female at least 18 years old

  • Diagnosis of bilateral open angle glaucoma or ocular hypertension

  • Unmedicated IOP must be ≥22mm Hg

Exclusion Criteria:
  • Any significant vision loss in the last year

  • No contact lens use for the length of the study

  • Abnormal eye lids, eye infection, or diseases to the eye

  • Recent eye surgery

  • Uncontrolled medication conditions

Contacts and Locations

Locations

Site City State Country Postal Code
1 Sall Research Medical Center, Inc Artesia California United States 90701
2 Wolstan & Goldberg Eye Associates Los Angeles California United States 90505
3 West Coast Eye Care Associates San Diego California United States 92115
4 Coastal Research Associates, LLC Roswell Georgia United States 30076
5 R and R Eye Associates San Antonio Texas United States 78229
6 Rocky Mountain Eye Care Associates Salt Lake City Utah United States 84107

Sponsors and Collaborators

  • Mati Therapeutics Inc.

Investigators

  • Study Director: Suzanne Cadden, QLT Inc.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Mati Therapeutics Inc.
ClinicalTrials.gov Identifier:
NCT01481051
Other Study ID Numbers:
  • PPL GLAU 12
First Posted:
Nov 29, 2011
Last Update Posted:
Sep 26, 2013
Last Verified:
Sep 1, 2013

Study Results

No Results Posted as of Sep 26, 2013